PCSK9 and metabolic syndrome: This reflects an absolute risk reduction of 9% and a relative risk reduction of 56%, underscoring the additive benefit of PCSK9 inhibitors for secondary prevention in high-risk diabetic patients with persistent dyslipidemia.